

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

CLAIMS

What is claimed is:

1. An isolated, enriched, or purified nucleic acid molecule encoding a novel mCLK2, mCLK3, or mCLK4 polypeptide.
2. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is isolated, enriched, or purified from a mammal.
3. The nucleic acid molecule of claim 1, wherein said molecule encodes at least seventeen contiguous amino acids of the mCLK2, mCLK3, or mCLK4 amino acid sequence.
4. A nucleic acid probe for the detection of a nucleic acid molecule encoding a mCLK2, mCLK3, or mCLK4 polypeptide in a sample.
5. A nucleic acid vector comprising a nucleic acid molecule encoding a mCLK2, mCLK3, or mCLK4 polypeptide and a promoter effective to initiate transcription in a recombinant cell.
6. A recombinant cell or tissue comprising a nucleic acid molecule encoding a mCLK2, mCLK3, or mCLK4 polypeptide.

7. An isolated, enriched or purified mCLK2, mCLK3, or mCLK4 polypeptide.
8. The isolated, enriched, or purified mCLK2, mCLK3, or mCLK4 polypeptide, wherein said polypeptide is a unique fragment comprising at least seventeen contiguous amino acids present in the full-length amino acid sequence set forth in Figure 1, Figure 2, Figure 4, or Figure 6.
9. An antibody or a antibody fragment having specific binding affinity to a mCLK2, mCLK3, or mCLK4 polypeptide.
10. A hybridoma which produces an antibody having specific binding affinity to a mCLK2, mCLK3, or mCLK4 polypeptide.
11. An isolated, enriched, or purified nucleic acid molecule comprising a nucleotide sequence that:
 - (a) encodes a full-length mCLK2, mCLK3, or mCLK4 amino acid sequence as set forth in Figure 1, Figure 2, Figure 4, or Figure 6.
 - (b) the complement of the nucleotide sequence of (a);
 - (c) hybridizes under highly stringent conditions to the nucleic acid molecule of (a) and encodes a naturally occurring mCLK2, mCLK3, or mCLK4 protein;

- (d) a mCLK2, mCLK3, or mCLK4 protein having the full length amino acid sequence as set forth in Figure 1, Figure 2, Figure 4, or Figure 6 except that it lacks one or more of the following segments of amino acid residues 1-182, 183-470, or 471-499 of mCLK2, 1-176, 177-473, or 474-496 of mCLK3, or 1-183, 184-486, or 486-489 of mCLK4;
- (e) the complement of the nucleotide sequence of (d);
- (f) a polypeptide having the amino acid sequence set forth in Figure 1, Figure 2, Figure 4, or Figure 6 from amino acid residues 1-182, 183-470, or 471-499 of mCLK2, 1-176, 177-473, or 474-496 of mCLK3, or 1-183, 184-486, or 486-489 of mCLK4;
- (g) the complement of the nucleotide sequence of (f);
- (h) encodes a polypeptide having the full length amino acid sequence set forth in Figure 1, Figure 2, Figure 4, or Figure 6 except that it lacks one or more of the domains selected from the group consisting of a N-terminal domain, a catalytic domain, and a C terminal-region; or
- (i) the complement of the nucleotide sequence of (h).

12. A nucleic acid vector comprising a nucleic acid molecule of claim 11.

13. A recombinant cell or tissue comprising a nucleic acid molecule of claim 11.

14. A method of identifying a compound capable activating or inhibiting CLK protein kinase phosphorylation activity, wherein said method comprises the following steps:

- (a) adding a compound to a mixture containing a CLK protein kinase polypeptide and a substrate for said CLK protein kinase; and
- (b) detecting a change in phosphorylation of said substrate.

15. A method of identifying compounds useful for diagnosis or treatment of an abnormal condition in an organism, wherein said abnormal condition is associated with an aberration in a signal transduction pathway characterized by an interaction between a CLK protein kinase polypeptide and a natural binding partner, comprising the following steps:

- (a) adding a compound to cells; and
- (b) detecting whether the compound promotes or disrupts said interaction between a CLK protein kinase polypeptide and a natural binding partner.

16. A method of diagnosing an abnormal condition associated with cell proliferation or RNA splicing in an organism, wherein said abnormal condition is associated with an aberration in a signal transduction pathway characterized by an interaction between a CLK protein kinase polypeptide and a natural binding partner, comprising the step of detecting said abnormal interaction.

17. The method of any one of claims 14-16, wherein said CLK protein kinase is isolated from a mammal.

18. The method of any one of claims 15-16, wherein said organism is a mammal.